Abnormally suppressed levels of cyclin-dependent kinase inhibitors (CKIs) are associated with aggressive androgenindependent prostate cancer and contribute to uncontrolled proliferation. The androgen-independent human prostate cancer cell lines, LNCaP-104R1, ALVA31 and PC-3, express low levels of the CKI, p21
Introduction
Most prostate cancer initially displays an androgendependent phenotype whose growth is inhibited by androgen deprivation therapy. However, these tumors invariably progress to an androgen-independent state and exhibit aggressive growth that is refractory to hormonal manipulation. The mechanisms by which prostatic tumors gain the capacity for uncontrolled, androgen-independent cellular proliferation are not understood. Although the relationship between p21 expression and prostate cancer prognosis is not clear cut (Matsushima et al., 1998; Aaltomaa et al., 1999 , Cheng et al., 2000 Fizazi et al., 2002) , decreased expression of cyclin-dependent kinase inhibitors (CKIs) has been proposed to explain how prostate tumor cells evade normal growth controls (Agus et al., 1999) . Consistent with this hypothesis, androgen-independent human prostate cancer cell lines typically contain lower levels of the CKIs, p21
CIP1 (Zhuang and Burnstein, 1998) and p27 KIP1 (Guo et al., 1997; Cipriano and Chen, 1998) compared to the relatively well-differentiated, androgen-dependent LNCaP line or normal prostate luminal epithelial cells (Zhuang and Burnstein, 1998; Waltregny et al., 2001; Yang et al., 2002) . A subline of LNCaP cells (LNCaP-R1) that have progressed to an androgen-independent state following prolonged androgen deprivation (Kokontis et al., 1994; Umekita et al., 1996) also exhibit lower p21 levels compared to the parental line (Kokontis et al., 1998; Yang et al., 2002) . Suppressed p21 levels are not a result of genetic mutations and cannot be completely accounted for by mutations in p53, a transcriptional regulator of p21 (Shiohara et al., 1994; Cipriano and Chen, 1998) . Alternatively, we have investigated the possibility that low levels of CKIs may result from aberrant intracellular signaling.
Progression through G1 phase is catalysed by cyclindependent kinases (CDKs) whose activities are determined by the relative levels of associated cyclins and CKIs (reviewed in Sherr, 1996) . Cyclin D1 binds and activates CDK4 (or CDK6) and cyclin E binds and activates CDK2 during G1 phase. In contrast, CKIs of the p21/p27 family inhibit G1 progression by binding to and suppressing the activity of cyclin E-CDK2 com-plexes. In nontransformed cells, p21 and p27 levels are regulated by mitogenic growth factors and cell adhesion to the extracellular matrix. As a result, in cycling cells, CKI concentrations are low, allowing activation of cyclin/CDK complexes which phosphorylate the retinoblastoma protein (pRb). Once phosphorylated, pRb's active repression of members of the E2F transcription factor family is relieved, allowing transcription of genes necessary for G1 to S transition. At higher CKI concentrations, the kinase activity of cyclin/CDK complexes is repressed resulting in decreased pRb phosphorylation and G1/G0 cell cycle arrest.
The Rho family GTPases are small cytosolic proteins classically known for their involvement in cytoskeletal rearrangements. Like other Ras-related GTPases, Rho proteins generally function as molecular switches that are activated when bound to GTP and cycle to an inactive GDP-bound state through hydrolysis of GTP. In addition to their role in cytoskeletal regulation, RhoA, Rac1, and Cdc42, the best characterized members of the Rho family, play an important role in multiple cellular processes, including cell migration, proliferation, and transformation (reviewed in Van Aelst and D'Souza-Schorey, 1997). Moreover, these Rho GTPases each appear to be necessary and sufficient for progression through the G1 phase of the cell cycle in fibroblasts (Olsen et al., 1995) . RhoA has been shown to specifically participate in signaling pathways controlling prostate epithelial cell proliferation using a cell line derived from transgenic mice exhibiting prostate adenocarcinoma (TRAMP model) (Ghosh et al., 1999; Ghosh et al., 2002) .
Activated Rho GTPases influence cell cycle progression at least partly through their ability to downregulate CKIs. Inactivation of RhoA with C. botulinum C3 exoenzyme (Sekine et al., 1989) or a dominant-negative RhoA mutant results in increased p21 expression in a variety of cell lines (Adnane et al., 1998; Auer et al., 1998; Olsen et al., 1998; Welsh and Assoian, 2000; Liberto et al., 2002) . Expression of constitutively active RhoA results in decreased transcription from the p21 promoter (Adnane et al., 1998) . RhoA has also been shown to antagonize oncogenic Ras (V12 H-Ras)-mediated induction of p21 in Swiss 3T3 cells (Olsen et al., 1998) . Conversely, inhibition of RhoA induced p21 expression in these cells.
Although a role for Rac1 or Cdc42 in p21 regulation has not been established, Rac1 participates in signaling cascades that converge on several genes associated with growth promotion including c-jun, serum response factor, and ATF-2 (Gupta et al., 1995; Minden et al., 1995) . Introduction of constitutively active Rac1 or Cdc42 mutants into NIH-3T3 fibroblasts results in increased pRb phosphorylation, E2F transcriptional activity, and cyclin D1 expression (Gjoerup et al., 1998) . In addition, Rat1 fibroblasts expressing a constitutively active Rac1 mutant display significantly increased proliferation as well as a partial loss of contact inhibition (Qiu et al., 1995) .
Overexpression and/or hyperactivity of specific Rho GTPases have been described for several tumor types.
RhoC is overexpressed in melanoma skin cancer and inflammatory breast cancer, both of which represent particularly aggressive forms of tumor (van Golen et al., 1999; Clark et al., 2000; van Golen et al., 2000) . Moreover, stable overexpression of RhoC confers a malignant phenotype to otherwise nontransformed human mammary epithelial cells (van Golen et al., 2000) . Mira et al. (2000) demonstrated that Rac3 is hyperactive in rapidly proliferating breast cancer cells, where it appears to be necessary for G1 to S phase transition. In addition, a hematopoietic-specific Rho family member, Rac2, is associated with an increased proliferative response in mast cells (Ingram et al., 2001) .
We investigated the relationship between p21 expression in prostate cancer cells and activity of Rho family GTPases. We found that the androgen-independent cell lines exhibited higher Rac1 activity compared to the androgen-dependent LNCaP cells, inversely correlating with their relative levels of p21. Inhibition of Rac1 increased p21 mRNA and protein in the androgen-independent cells but not in LNCaP cells. Further, this upregulation of p21 inhibited CDK2 activity and cell proliferation. Conversely, expression of a constitutively active Rac1 mutant (Rac1V12) suppresses the higher levels of p21 seen in LNCaP cells. Our findings suggest that hyperactive Rac1 underlies suppression of p21, thereby enhancing cellular proliferation in the androgen-independent prostate cancer cell lines.
Results
p21 expression is lower in aggressive, androgenindependent prostate cancer cells compared to androgendependent LNCaP cells
We chose four human prostate cancer cell lines as models to analyse differences in cell cycle regulation between androgen-dependent and -independent phenotypes. LNCaP cells are a less malignant, androgendependent, human prostate cancer cell line (reviewed in Navone et al., 1998 Navone et al., -1999 . LNCaP-R1, ALVA31, and PC-3 cells represent a more aggressive, androgenindependent phenotype. Unlike LNCaP cells, these androgen-independent cell lines readily form tumors in castrated nude mice and are not dependent on growth factors or serum for growth (Tilley et al., 1990; Loop et al., 1993 Loop et al., , 1995 Kokontis et al., 1994; Umekita et al., 1996) . Both LNCaP and LNCaP-R1 express androgen receptors, whereas androgen receptor is not detectable in ALVA31 and PC3 cells (Kokontis et al., 1994) Figure 1 illustrates that in asynchronously growing cultures, androgen-independent cell lines expressed low to undetectable levels of p21, whereas LNCaP cells maintained higher p21 expression. Cyclin D1 levels did not vary substantially between the four cell lines (Figure 1 ). CDK4, which remains constant under various growth conditions, was used as a loading control.
Inhibition of Rho GTPases causes upregulation of p21 exclusively in androgen-independent prostate cancer cell lines
To evaluate the role of Rho family GTPases in regulating p21 in prostate cancer cells, we used an inhibitor of the Rho family members, C. difficile toxin A (Aktories and Just, 1995) . This toxin specifically inactivates Rho GTPases by glucosylation of a pivotal threonine residue in the effector-binding region and has the advantage of readily entering cells via receptormediated endocytosis. Toxin A has no effect on Ras proteins (Aktories and Just, 1995) . Following treatment, p21 was upregulated in LNCaP-R1 (threefold), ALVA31 (twofold) and PC-3 (2.5-fold) but not in LNCaP cells (Figure 2a and b) . Cyclin D1, which is regulated by Rac1 in several cell types (24, 37-39), was not affected by toxin A in these prostate cancer cell lines (Figure 2a ).
Rac1 is hyperactive in androgen-independent prostate cancer cell lines compared to LNCaP cells
In order to address the differential effect of Rho inhibition on p21, we compared the activity of endogenous Rho GTPases in androgen-independent and LNCaP cells. The activity assay takes advantage of the selective ability of activated GTPases to bind to their respective effectors (see Materials and methods). Both GTP-bound Rac1 and Cdc42 bind the effector protein PAK (p21-activated kinase). For these experiments, the Rac/Cdc42-binding domain of PAK was used to 'pull down' activated Rac/Cdc42 GTPases. The activity of Rac1 was markedly higher in the aggressive lines (LNCaP-R1, ALVA31, and PC-3 cells) relative to LNCaP cells (Figure 3a ). For reference, approximately 2% of total Rac1 is GTP-bound in LNCaP cells, whereas Rac1 activity was twofold higher in LNCaP-R1 cells, 16-fold higher in ALVA31 cells, and 21-fold higher in PC-3 cells (Figure 3b ). The elevated levels of Rac1 activity in the androgen-independent cell lines were not due to overexpression of Rac1 protein, which was comparable in the four prostate cancer cell lines ( Figure  3a and c).
In contrast to Rac1 activity, Cdc42 activity was barely detected in the four cell lines (Figure 3d ). When cell lysates were preloaded with non-hydrolyzable guanosine 5 0 -[g-thio]triphosphate (GTPgS), GTP-Cdc42 was apparent indicating that the assay can detect GTP-bound Cdc42 but that endogenous activity is low (data not shown). RhoA activity was comparable and relatively low in all four cell lines with approximately 3-4% GTPbound RhoA (data not shown).
Rac1 is necessary for downregulation of p21 expression
The GTPase-binding domains of Rho effector proteins are commonly used to inhibit specific Rho family members. In order to inhibit Rac1, we introduced a GST fusion protein containing the p21-binding domain (PBD) from the Rac/Cdc42 effector protein PAK, which selectively binds and sequesters the activated forms of Rac1 and Cdc42. This binding to activated Rac1/Cdc42 thereby blocks interaction with downstream targets (Benard et al., 1999) . Introduction of PBD increased p21 levels in androgen-independent prostate cancer cells but had no effect on p21 in LNCaP cells (Figure 4a ). The p21 levels were upregulated on an average of twofold in LNCaP-R1, 5.5-fold in ALVA31, and fivefold in PC-3 cells (Figure 4b ). We assessed the efficiency of protein uptake in the four cell lines using a GST-GFP fusion protein followed by FACS analyses. The indicated androgen-dependent (AD) and -independent (AI) prostate cancer cell lines were treated with Toxin A (200 ng/ml) or vehicle (sterile, distilled H 2 O) as described in Materials and methods. (a) Total protein (100 mg) from each cell line was resolved by SDS-PAGE and immunoblotted with antiserum to p21, cyclin D1, and CDK4 (loading control). (b) A summary of p21 regulation from five to seven independent experiments quantified using densitometry. Significance was determined by a Student's t-test, *Po0.05 Figure 1 LNCaP cells express higher levels of p21 than androgenindependent cell lines. Lysates were obtained from asynchronous cultures of LNCaP, ALVA31, PC-3, and LNCaP-104R1 (LNCaP-R1) cells. Increasing amounts of protein (12.5, 25, or 50 mg) from each lysate were resolved by SDS-PAGE on 15% gels. Proteins were transferred to nitrocellulose membranes and immunoblotted for p21, cyclin D1, or CDK4 (loading control). The blot shown is representative of one to three experiments Rac1 regulation of p21 CIP1 in prostate cancer S Knight-Krajewski et al Efficiency of uptake ranged from 7-23% and was highest in LNCaP cells, suggesting that the lack of p21 regulation in these cells following PBD treatment is not due to less efficient uptake of fusion protein ( Figure 4c ).
As was observed for p21 protein, introduction of PBD caused induction of p21 mRNA exclusively in androgenindependent cells (Figure 4d ). In treated ALVA31 and PC-3 cells, p21 mRNA levels reached comparable levels to those observed in LNCaP. p21 mRNA was only modestly elevated in LNCaP-R1 cells which correlated well with the small increase in p21 protein in these cells (Figure 4a and b) .
The actions of PBD most likely result from inhibition of Rac1 because of the extremely low activity level of Cdc42 in these prostate cancer cells. However, inasmuch as PBD inhibits both GTPases, we also used dominantnegative mutants to specifically inhibit Rac1 or Cdc42. These dominant-negative mutants (Rac1N17, Cdc42N17) function by sequestering upstream activators or guanine nucleotide exchange factors, but have no intrinsic catalytic activity (Zhang et al., 1995) . Transient expression of HA-tagged Rac1N17 (Figure 5a ) but not HA-tagged Cdc42N17 (Figure 5b ) resulted in an increase in p21 levels in androgen-independent cells but not in LNCaP cells supporting and extending the results seen with PBD treatment.
Activated Rac1 attenuates p21 levels in androgendependent cells
To analyse further the possibility that hyperactivation of Rac1 underlies the suppression of p21, we used a constitutively activated mutant, Rac1V12, which is deficient in GTPase activity. Transient expression of Rac1V12 in LNCaP cells (Figure 6a ) attenuates the usually high p21 levels that characterize this cell line (Figure 6b ). Taken together with the previous result, Rac1 appears to be necessary and sufficient to lower p21 levels in prostate cancer cells. The data also support the notion that the activation level of Rac1 plays an important role in influencing p21 levels in these prostate cancer models.
Rac1 inhibition suppresses CDK2 activity and cell proliferation p21 antagonizes progression through G1 primarily by binding to and inhibiting the activity of cyclin E-CDK2 complexes. In order to determine whether the PBD- Figure 3 Rac1 activity but not total Rac1 levels are higher in androgen-independent cells. (a) GTP-bound Rac1 was separated from GDP-Rac1 using a pull-down assay as described in Materials and methods. Cell lysates were incubated with 200 mg/ml PBD-GST (p21-binding domain, PBD, of the Rac1/Cdc42 effector PAK (p21-activated kinase)). GTP-Rac1 was recovered following incubation with glutathione-agarose beads. Complexes were collected, denatured and resolved by SDS-PAGE. Active Rac1 (GTP-Rac1) was detected by Western blotting with anti-Rac1 antibodies. Total Rac1 (GDP-and GTP-bound) represents 5% of the original cell lysate. Actin is used as a loading control. (b) Quantitative results of six to 13 independent experiments for Rac1 activity are shown. (c) Five independent experiments for total Rac1 levels by Western blotting of cell lysates are shown normalized to actin. Significance was determined using Student's t-test. *Po0.05. (d) GTP-bound Cdc42 was isolated as described for GTP-bound Rac1. Active Cdc42 (GTP-Cdc42) was detected by Western blotting with antiCdc42 antibody. Total Cdc42 (GDP-and GTP-bound) represents 5% of the original cell lysate. Actin is used as a loading control Rac1 regulation of p21 CIP1 in prostate cancer S Knight-Krajewski et al induced upregulation of p21 is functionally significant, we analysed the kinase activity of CDK2 immunoprecipitates. Treatment with PBD promoted the association of p21 with CDK2 and inhibited CDK2 activity in androgen-independent cells (approximately 70% reduction in ALVA31 and 40% in PC3 cells) (Figure 7 ). In contrast, untreated LNCaP had high levels of complexed p21 along with lower CDK2 activity and these did not change after treatment with PBD.
To assess effects of Rac1 inhibition on cell proliferation, we performed 3 H thymidine uptake assays. PBD treatment resulted in a marked decrease in 3 H thymidine incorporation in ALVA31 and PC-3 cells but there was no significant difference in LNCaP cells. PBD produced a small decrease in 3 H thymidine incorporation in LNCaP-R1 relative to the other androgen-independent Figure 4 Inhibition of Rac1 and Cdc42 with PBD results in upregulation of p21 protein and mRNA in androgen-independent cell lines. In total, 40 mg PBD-GST protein, GFP-GST, or equivalent molar ratios of GST were introduced into the indicated cell lines (as described in Materials and methods) and lysates were obtained after 24 h. (a) Total protein (50 mg) was immunoblotted with the indicated antibodies. Cdk4 was used as a loading control. (b) Band intensity was quantified using densitometry from five to six experiments. Significance was determined using Student's t-test; *Po0.05. (c) Efficiency of protein uptake was determined by FACS analyses in cells incubated with GFP-GST. The percentage of fluorescent cells is indicated for each of the cell lines. (d) Total RNA was isolated from cells 16 h following treatment with GST or PBD-GST. Membranes containing 20 mg total RNA were probed sequentially with 32 P-labeled p21 and GAPDH cDNA probes and exposed to film. The Northern blot shown is representative of two to three independent experiments Figure 5 Expression of dominant-negative Rac1 (Rac1N17) results in p21 upregulation in androgen-independent cells. Dominant-negative Rac1 (a) or Cdc42 (b) cDNA mutants (Rac1N17, Cdc42N17) tagged with hemagluttinin (HA) were transiently transfected into LNCaP, ALVA31, and PC-3 cells. Cells were harvested and lysed 48 h after transfection. Top panels of a and b, Western blots probed with anti-HA antibody confirm expression of Rac1N17 and Cdc42N17 in LNCaP, ALVA31, and PC-3 cells. Lower panels of a and b, Western blots performed in parallel show effects of Rac1N17 and Cdc42N17 on p21. The blots shown are representative of two experiments. Transfection efficiency was determined using a plasmid encoding yellow fluorescent protein (YFP) and was found to be comparable for all three cell lines Rac1 regulation of p21 CIP1 in prostate cancer S Knight-Krajewski et al cells, consistent with its modest ability to induce p21 in these cells (Figure 8) . Thus, the increased p21 expression resulting from Rac1 inhibition abrogates cell proliferation in androgen-independent cells, consistent with inhibition of CDK2 activity.
Discussion
We examined a possible role for Rho GTPases in controlling p21 levels in prostate cancer cells. Our data support the hypothesis that higher levels of Rac1 activity (but not overexpression of Rac1 protein) in aggressive androgen-independent prostate cancer cells contributes to suppression of the CKI p21 and uncontrolled cell growth. Thus, inhibition of Rac1 with either a dominant-negative mutant or a competing effector protein, PBD, resulted in p21 upregulation in LNCaP-R1, ALVA31, and PC-3 but not LNCaP cells. In androgen-independent cells with pronounced Rac1 hyperactivity (ALVA31 and PC3), there was a marked induction of p21 upon Rac inhibition with PBD. This was associated with suppressed CDK2 activity as well as decreased proliferation. Conversely, expression of a constitutively active Rac1 mutant decreased p21 in LNCaP cells. Of the androgen-independent cell lines, LNCaP-R1 cells exhibited both the lowest Rac1 activity and the smallest increases in p21 mRNA and protein.
Further, PBD only modestly reduced proliferation in these cells suggesting that other mechanisms, in addition to Rac1, may be relevant to this model of androgen independence.
Rac1 promotes G1 to S phase progression in a variety of cell types through increasing cyclin D1 transcription, pRb phosphorylation, and E2F activity (Gjoerup et al., 1998) but effects on p21 expression are not well established. Recently, Rac1 and Cdc42 were shown to play a role in integrin-mediated pathways that lead to p21 proteasomal degradation (Bao et al., 2002) . Since Rac1 inhibition induces p21 mRNA expression in androgen-independent prostate cancer cell lines, degradation of p21 does not represent the likely mechanism in this case. Although Rac1 has been shown to regulate cyclin D1 expression in several other cell lines (Westwick et al., 1997; Gjoerup et al., 1998; Gille and Downward, 1999; Joyce et al., 1999; Page et al., 1999; Welsh et al., 2001) , inhibition of Rac1 did not influence cyclin D1 levels in the human prostate cancer cell lines (Figure 2a) . Likewise, effects on the CKI p27 were modest and less consistent than those observed for p21 (data not shown). Data presented here support a novel role for Rac1 in regulating prostate cancer cell proliferation via actions on p21. H thymidine uptake was conducted as described in Materials and methods. Results of three to six independent experiments carried out in triplicate are shown. Significance was determined using Student's t-test; *Po0.05, **Po0.01
Rac1 regulation of p21 CIP1 in prostate cancer S Knight-Krajewski et al Increased p21 expression contributes to G1/G0 cell cycle accumulation, whereas cells lacking or containing low levels of CKIs exhibit continuous and rapid passage through the cell cycle (reviewed in Sherr, 1996; Sherr and Roberts, 1999) . Specifically, p21 promotes the formation of cyclin D/CDK4 complex; however at higher concentration, p21 binds cyclin E/CDK2 as well as cyclin A/CDK2 and thereby functions as an inhibitor of CDK2 activity. p21 may inhibit cell proliferation not only through decreasing CDK2 activity, but also through other mechanisms such as by interacting with proliferating cell nuclear antigen (PCNA) and decreasing DNA replication (Flores-Rozas et al., 1994; Waga et al., 1994; Luo et al., 1995) . However, our data suggest that inhibition of Rho GTPases produces G1/G0 accumulation in prostate cancer cells. For example, treatment with Toxin A resulted in an increase in the ratio of hypo-to hyperphosphorylated pRb in PC3 cells and G0/G1 accumulation by FACS analysis in ALVA31 cells (data not shown).
The increase in p21 upon Rac1 inhibition in androgen-independent cells appears to occur through regulation of p21 transcription since p21 mRNA is also induced. Both ALVA31 and PC-3 cells lack the p53 tumor suppressor protein (Rubin et al., 1991; van Bokhoven et al., 2001 ), a major regulator of p21 transcription. Thus, p21 induction seen with Rac1 inhibition in ALVA31 and PC-3 cells can be added to the growing list of examples of p53-independent regulation of p21. Similarly, in a variety of p53-null carcinoma cells, geranylgeranyltransferase-I inhibitor (an inhibitor of Rho GTPase activation) arrests cells in G1 phase via p21 upregulation (Vogt et al., 1997) . However, LNCaP cells, and presumably LNCaP-R1 cells, express wild-type p53 (Gartel and Tyner, 1999) and therefore a role for p53 in Rac1 regulation of p21 in LNCaP-R1 cells cannot be formally excluded. p53-independent p21 transcription can occur through a wide variety of agents that signal to different transcription factors including AP2, Sp1-3, STATs, E2Fs, and members of the basic helix-loop-helix family (reviewed in Carroll et al., 1993) . Some of these transcription factors interact with p300/CBP, which possesses histone acetyltransferase activity, to regulate the p21 promoter (Carroll et al., 1993) . The mechanism by which Rac1 suppresses p21 mRNA levels is not known.
The role of p21 in cancer progression is not clear nor is there consensus on the utility of p21 as a prognostic indicator (reviewed in Tsihlias et al., 1999) . However, new studies support p21 as a gatekeeper in preventing uncontrolled prostate cancer proliferation. A recently discovered protein, Kruppel-like factor 6 (KLF6), appears to be a tumor suppressor in prostate cancer as one KLF6 allele is deleted in 77% of primary prostate tumors and the retained allele is mutated in 71% of those cases. Importantly, KLF6, which is a putative transcription factor, induces p21 in PC3 cells and inhibits cell proliferation (Narla et al., 2001) . The high rate of KLF6 mutations in prostate cancer thus supports the importance of p21 as an inhibitor of prostate cell proliferation and highlights its potential role in prevention of prostate cancer progression.
Rac1 activity is significantly higher in the androgenindependent cell lines, LNCaP-R1, ALVA31 and PC-3 cells compared with LNCaP cells (Figure 3) . Similarly, Rac3, has been reported to be hyperactive in rapidly proliferating breast cancer cells but not in normal mammary epithelial cells or slower growing cancer cells (Mira et al., 2000) . Hyperactivity of Rac1 (and Rac3) in more aggressive cancer cells may be due to alterations in upstream activators or repressors of the Rho family. The activity cycle of Rho GTPases depends primarily on two classes of regulatory proteins, guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs) (reviewed in Van Aelst and D'SouzaSchorey, 1997; Zohn et al., 1998) . GEFs, initially discovered as oncogenic proteins in fibroblasts (Van Aelst and D'Souza-Schorey, 1997; Zohn et al., 1998) , activate cytosolic GTPases by stimulating the exchange of bound GDP for GTP. GAPs accelerate the rate of bound GTP hydrolysis, resulting in inactivation of the GTPase. For example, active Tiam1, a GEF specific for Rac, recapitulates the cytoskeletal effects of active Rac1 when expressed in NIH-3T3 fibroblasts, placing it upstream of Rac in specific signaling pathways in vivo (Michiels et al., 1995) . Thus, one possible explanation for the observed Rac1 hyperactivity in aggressive prostate cancer cells is activation of a Rac-specific GEF.
An alternative explanation for Rac1 hyperactivity is decreased activity of a GAP specific for Rac1. Although there are little data regarding decreased Rho GAP activity in carcinomas, this possibility cannot be excluded. Low expression of RasGAP, known to significantly depress Ras activity, has been shown for invasive carcinomas whereas RasGAP is expressed at high levels in noninvasive tissue (Stahle-Backdhal et al., 1995) . Another known GAP for Ras, NF1, is capable of triggering cancer when one Nf1 allele is mutated in mice (Reed and Gutmann, 2001) . Furthermore, decreased expression of the Ras GAP DAB2IP is seen in metastatic prostate cell lines compared with normal prostate epithelial and primary prostate tumors (Chen et al., 2002) . Whether differences in expression levels of a GAP for Rac1 may contribute to increased Rac1-GTP and lead to increased tumor cell proliferation in androgen-independent cells remains to be determined.
Based on the present study, normalizing levels of p21 by targeting Rac-dependent signaling pathways may help control prostate cancer growth following emergence of the androgen-independent phenotype. Further studies are needed to address whether Rac1 hyperactivity correlates with other clinical parameters including tumor grade, and whether Rac1 signaling may serve as a therapeutic target following progression to androgen independence.
Materials and methods

Materials
Cell culture media (RPMI-1640 and DMEM-H) were purchased from Gibco-BRL (Gaithersburg, MD, USA), and FBS from Hyclone (Logan, UT, USA). C. difficile Toxin A was a Rac1 regulation of p21 CIP1 in prostate cancer S Knight-Krajewski et al generous gift of Dr David Lyerly (Techlab, Blacksburg, VA, USA). Glutathione S-transferase (GST) tagged PAK-binding domain (PBD) is cloned into pGEX expression vector and was provided by Dr Margaret Chou (University of Pennsylvania) and GFP-GST was provided by Dr Andrew Wilde (University of Toronto). BL-21 competent cells were purchased from Invitrogen (Carlsbad, CA, USA). Bulk GST purification module was purchased from Amersham Pharmacia Biotech, Inc.
(Piscataway, NJ, USA). Dominant-negative (Rac1N17Cdc42N17) and constitutively active (Rac1V12) mutant constructs of Rac1 were provided by Dr Martin Schwartz (Scripps Research Institute). The following antibodies for Western blotting were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA): p21, cyclin D1, CDK4, CDK2, myc. Rac1 and Cdc42 antibodies were purchased from Upstate Biotechnology (Lake Placid, NY, USA); HA antibody from Covance (Richmond, CA, USA); GST antibody from Amersham Pharmacia Biotech, Inc. (Piscataway, NJ, USA).
Cell culture
The human prostate cancer cell lines LNCaP.FGC (LNCaP (ATCC cat. no. CRL1740; batch F-11701))] and PC-3 (ATCC cat. no. CRL 1435; batch F-11154) were obtained from American Type Culture Collection (Rockville, MD, USA). The human prostate carcinoma cell line ALVA 31 (Loop et al., 1993 (Loop et al., , 1995 was generously provided by Drs Stephen Loop and Richard Ostenson (Department of Veterans Affairs Medical Center, Tacoma, WA, USA). The human prostate cancer cell line LNCaP 104-R1 (Kokontis et al., 1994; Umekita et al., 1996) was generously provided by Drs John Kokontis and Shutsung Liao (University of Chicago). Briefly, LNCaP cells express androgen receptor and exhibit androgen-dependent growth (Horoszewicz et al., 1983) ; ALVA 31 and PC-3 cells do not contain detectable levels of androgen receptor and the growth of these cells is not affected by androgen (Tilley et al., 1990; Loop et al., 1993 Loop et al., , 1995 . LNCaP-R1 cells are AR positive and are a subline of LNCaP cells generated following prolonged culture in the absence of androgens (Kokontis et al., 1994; Umekita et al., 1996) . LNCaP-R1 cells were grown in DMEM containing 50 IU/ml penicillin and 50 mg/ml streptomycin (Gibco-BRL, Gaithersburg, MD, USA), and 10% charcoal-stripped (CS) FBS. LNCaP, ALVA 31, and PC-3 cell lines were cultured in RPMI-1640 containing 100 IU/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine (Gibco-BRL, Gaithersburg, MD, USA), and 10% FBS.
Toxin A studies
Approximately 8 Â 10 6 cells were seeded in 100 mm dishes and treated 24 h later with 200 ng/ml Toxin A or vehicle (sterile, distilled H 2 O). Cells were retreated with toxin the following day. At 48 h after the initial Toxin A treatment, cells were harvested for Western blotting. Plates were placed on ice, washed with ice-cold 1 Â PBS and scraped from the plate. The cells were lysed in 50 mM Tris, pH 7.4, 250 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 50 mM NaF, and 0.1 mM NaVO 4 . After a 5 min incubation on ice, lysates were briefly centrifuged and supernatant collected. Protein concentration was determined using the Bio-Rad D c Protein assay (Bio-Rad, Hercules, CA, USA). Equal amounts of total protein per sample, 50-100 mg, was subjected to SDS-PAGE and transferred to nitrocellulose membrane. The membranes were processed for immunoblotting using standard techniques. The following primary antibodies were used at a concentration of 1 mg/ml: p21, cyclin D1, and CDK4 from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Proteins were visualized using enhanced chemiluminescence (ECL, Amersham, Buckinghamshire, UK). Densitometric analysis was performed using a Molecular Dynamics Personal Densitometer SI (Sunnyvale, CA, USA).
Rho GTPase activity assays
To assess Rac1 or Cdc42 activity, we performed pull-down assays using the Rac/Cdc42-binding domain (p21-binding domain, PBD) of p21-activated kinase (PAK). Cells were plated at a density of approximately 8 Â 10 6 cells in 100 mm dishes and harvested 48 h later. Cell monolayers were washed with ice-cold 1 Â PBS and immediately lysed in Mg 2 þ lysis buffer (12.5 mM HEPES, 75 mM NaCl, 5 mM MgCl 2 , 0.5% Igepal CA-630, 0.5 mM EDTA, 10% glycerol, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 50 mM NaF, and 0.1 mM NaVO 4 ) containing 200 mg/ml PBD-GST. Cell lysates were briefly centrifuged and supernatants collected for the assay. Protein concentration was determined. For each experiment, equal amounts of total protein per sample, 0.5-1 mg, were immediately added to 50 ml glutathione sepharose beads. The mixture was gently shaken at 41C for 45 min. The sepharose beads were pelleted and the complexes washed three times with 1 Â lysis buffer not containing PBD-GST. Bound protein (GTP-bound Rac1 or GTP-bound Cdc42) was eluted with SDS sample buffer and separated by SDS-PAGE. A total of 5% of the original lysate was also electrophoresed to determine total levels of Rac1 or Cdc42 GTPase (GDP-and GTP-bound). Proteins were transferred to nitrocellulose membrane and Western blotting was performed. All samples were analysed by immunoblot using the following antibodies (Upstate Biotechnology) at a concentration of 1 mg/ml: antiRac1 (for Rac1 pull-down assay) or anti-Cdc42 (for Cdc42 pull-down assay) antibodies and visualized using ECL and quantified as described above.
PBD-GST protein purification and protein transfection
GST,PBD-GST and GFP-GST proteins were purified using the bulk GST purification module as described by the manufacturer (Amersham Pharmacia Biotech, Inc.). BL-21 competent cells were transformed with expression plasmids encoding GST fusion proteins and grown to log phase. Gene expression was induced with 100 mM isopropyl b-D-thiogalactoside for 90 min. Cell lysates were added to glutathione columns, then eluted with reduced glutathione. Purified protein concentration was determined using Bio-Rad D c Protein assay. Approximately 8 Â 10 6 cells were seeded in 100 mm dishes 16-20 h prior to protein transfection. Purified PBD-GST (40 mg) or the molar ratio of purified GST (as control) was incubated with 20 ml Lipofectamine Plus (Gibco-BRL, Gaithersburg, MD, USA) per 100 mm dish for 15 min at room temperature and then incubated with 60 mg Lipofectamine for an additional 15 min. The mixture was added to prostate cancer cell lines and placed at 371C for 3 h. FBScontaining media was replaced with the transfection media and cells were harvested 24 h later for Western blotting as described above. To assess the efficiency of protein uptake, cells were incubated with GFP-GST as described above and the percent of fluorescent cells determined by FACS. Briefly, cells were washed with ice-cold 1 Â PBS twice, trypsinized and pelleted. Cells were resuspended in 1 Â PBS and counted. Approximately 500 000 cells were resuspended in 0.5 ml of fixing solution (1 Â PBS, 1 mM EDTA, and 1% paraformaldehyde) followed by FACS analysis using FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA).
Cell transfection
Approximately 8 Â 10 6 cells were seeded in 100 mm dishes 16-20 h prior to transfection and the medium was changed to unsupplemented DMEM (without antibiotic or FBS) 90 min prior to transfection. Rac1N17 (2 mg) or the control vector pcDNA3 were transfected into cells using calcium phosphate method (Sambrook et al., 1989) . Cells were incubated with the DNA precipitates for 5-6 h at 371C followed by a 1 min glycerol shock (15% glycerol in DMEM). Plates were washed one time and refed with fresh media. Rac1V12 or pcDNA3 (10 mg) as control were transfected into cells using Lipofectamine and Lipofectamine PLUS, according to the manufacturer's instructions. To assess transfection efficiency, parallel cell cultures were transfected with a YFP-encoding plasmid, pEYFP-C1 (Clontech, Palo Alto, CA, USA). The number of fluorescent cells and the total number of cells from 10 random fields (approx. 70-90 cells per field) were counted.
Northern blot
Northern blotting was performed as previously described (Zhuang and Burnstein, 1998) . Briefly, total RNA was isolated using TRIzol reagent (GIBCO, Grand Island, NY, USA) according to the manufacturer's instructions. Total RNA (20 mg) was denatured and electrophoresed in a 1% agarose gel containing 0.66 M formaldehyde and transferred to a nylon membrane (Boehringer Mannheim). Blots were hybridized with 32 P-labeled p21 or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA probes as previously described (Zhuang and Burnstein, 1998) .
Immunoprecipitation and in vitro kinase assay
GST or PBD-GST proteins were introduced into cells as described above. CDK2-containing complexes were isolated by incubation of 200 mg cell lysate proteins with 2 mg CDK2 rabbit polyclonal antibody for 1 h at 41C with agitation followed by 1 h incubation with 35 ml anti-rabbit IgG agarose beads (Sigma-Aldrich). The immune complexes were collected by centrifugation and washed one time with lysis buffer and three times with kinase assay buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl 2 ). Complexes were incubated with 30 ml kinase assay mix (1 mg histone H1, 25 mM ATP, 10 mCi [g 32 P]ATP) for 30 min at 301C. The reactions were stopped with the addition of 4 Â sample buffer. Samples were boiled, subjected to SDS-PAGE, transferred to nitrocellulose and detected by autoradiography. The amount of CDK2 present in immunocomplexes was determined by immunoblot.
[ 3 H] thymidine uptake Cells were plated in six-well dishes at a density of approximately 1.5 Â 10 6
. Cells were transfected with either GST or PBD-GST proteins as described above. Following the transfection, media were replaced with 3 H thymidine-containing media (1 mCi 3 H/well). Cultures were incubated at 371C for 18 h and washed with ice-cold 1 Â PBS. Acid-soluble radioactivity was removed by a 20 min incubation with 5% TCA at 41C followed by two washes with 100% ethanol. Cells were solubilized with 0.1 M NaOH, 2% Na 2 CO 3 , and 1% SDS for 30 min at 371C and incorporated radioactivity was determined by liquid scintillation counting.
